TIRZ
Dual GIP/GLP-1 receptor agonist. In the SURMOUNT-1 Phase 3 trial, mean weight reduction was 15-21% at 72 weeks vs 3.1% with placebo. Brand names include Mounjaro and Zepbound. Tirzepatide is a prescription-only medication and must be obtained and used under the supervision of a licensed healthcare provider.
Regulatory status (as of Sept 2026)
FDA-approved. Removed from the FDA shortage list, so compounding of copies is restricted.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote2 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Tirzepatide is an FDA-approved prescription drug. Dual GIP/GLP-1 receptor agonist.
| Half-life | About 5 days |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | FDA-approved |
| Dosing | Published research: Humans: 5, 10 or 15 mg subcutaneous once weekly for 72 weeks after a 20-week escalation, n=2539 detailsHumans: 5, 10 or 15 mg s.c. once weekly for 72 weeks after a 20-week escalation, n=2539 (SURMOUNT-1, Jastreboff 2022). Phase 1: 0.25-15 mg (Coskun 2018).Community-reportedCommunity-reported: 2.5–15 mg weekly, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It acts on two gut-hormone receptors (GIP and GLP-1) and led to weight loss in a clinical trial. Dual GIP and GLP-1 receptor agonist, developed to test whether GIP's metabolic action adds to GLP-1 receptor agonism (Coskun 2018). Its effect on body weight comes from clinical trials: in the SURMOUNT-1 phase 3 RCT (n=2539), mean weight change at 72 weeks was -15.0% to -20.9% with 5-15 mg weekly vs -3.1% with placebo (Jastreboff 2022).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedSome users report running Tirzepatide at 2.5–15 mg weekly (subcutaneous injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Tirzepatide | ~5 days | Subcutaneous injection | FDA-approved |
| 5-Amino-1MQ | Unknown | Oral | Preclinical (animal) |
| AOD-9604 | No published PK data found | Subcutaneous injection | Discontinued |
| Adipotide (FTPP) | No published PK data found | Subcutaneous injection | Preclinical (animal) |
| Dulaglutide | ~5 days | Subcutaneous injection | FDA-approved |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Metabolic category. View All Metabolic Peptides
From Our Affiliated Clinic
1836 Wellness offers physician-supervised medical weight loss in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
Learn about medical weight loss →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.